Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829 · View on ClinicalTrials.gov ↗
Study Summary
This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the safety and tolerability of Lu AG13909. 3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).
Conditions Studied
Interventions
- DRUG Lu AG13909
Study Locations (20)
Other
- Hopital Louis Pradel — Bron
- APHP - Hôpital Bicêtre — Le Kremlin-Bicêtre
- Centre Hospitalier Universitaire De Lille — Lille
- Hopital Haut-Leveque — Pessac
- Ltd Aversi Clinic — Tbilisi
- Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika — Budapest
- Debreceni Egyetem Klinikai Kozpont — Debrecen
- University Hospital of Pecs — Pécs
- AOU Policlinico G. Martino — Messina
- Azienda Ospedaliera Universitaria Sant'Andrea — Rome
- AOU Citta della Salute e della Scienza di Torino — Torino
- Institutul National de Endocrinologie "C.I. Parhon" — Bucharest
Europe
- Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital La Conception — Marseille
- Ltd Tbilisi Central Hospital — Tbilisi
- National Institute of Endocrinology — Tbilisi
- Multiprofile Clinic Consilium Medulla Ltd — Tbilisi
- Azienda Ospedale Università di Padova — Padua
- Azienda Ospedaliero-Universitaria Pisana — Pisa
Michigan
- University of Michigan — Ann Arbor
Cedex 09
- Centre Hospitalier Universitaire d'Angers — Angers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06471829
The ClinicalTrials.gov registry entry for NCT06471829 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 17 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cushing's Disease appearing as the primary indexed condition, and to 1 intervention — of which Lu AG13909 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06471829 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Other, Europe, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06471829 about?
NCT06471829 is a clinical study titled "A Trial of Lu AG13909 in Adult Participants With Cushing's Disease". This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about 1. the effect of Lu AG13909 on cortisol levels. 2. the ...
What is the current status of trial NCT06471829?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-06-19. Estimated completion is 2027-11-30.
What conditions does trial NCT06471829 study?
This clinical trial studies the following conditions: Cushing's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06471829?
The interventions under investigation include: Lu AG13909 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06471829?
This trial is sponsored by H. Lundbeck A/S, which has 17 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06471829 being conducted?
This trial has 20 study locations across Michigan, Cedex 09, Europe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.